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Association of Serum-Soluble Heat Shock Protein 60 With
Carotid Atherosclerosis
Clinical Significance Determined in a Follow-Up Study
Qingzhong Xiao, MD; Kaushik Mandal, MD; Georg Schett, MD; Manuel Mayr, MD, PhD;
Georg Wick, MD; Friedrich Oberhollenzer, MD; Johann Willeit, MD;
Stefan Kiechl, MD; Qingbo Xu, MD, PhD
Background and Purpose—Previous work has shown that soluble heat shock protein 60 (HSP60; sHSP60), present in
circulating blood, is associated with carotid atherosclerosis. In the current evaluation, we tested the hypothesis that
sHSP60 levels are associated with the progression of carotid arteriosclerosis, prospectively.
Methods—The association of sHSP60 with early atherogenesis (5-year development and progression of nonstenotic carotid
plaques) was investigated as part of the population-based prospective Bruneck Study. The current study focused on the
follow-up period between 1995 and 2000 and, thus, included 684 subjects.
Results—sHSP60 levels measured in 1995 and 2000 were highly correlated (r0.40; P0.001), indicating consistency
over a 5-year period. Circulating HSP60 levels were significantly correlated with antilipopolysaccharide and anti-HSP60
antibodies. It was also elevated in subjects with chronic infection (top quintile group of HSP60, among subjects with
and without chronic infection: 23.8% versus 17.0%; P0.003 after adjustment for age and sex). HSP60 levels were
significantly associated with early atherogenesis, both in the entire population (multivariate odds ratio, for a comparison
between quintile group V versus III: 2.0 [1.2 to 3.5] and the subgroup free of atherosclerosis at the 1995 baseline: 3.8
[1.6 to 8.9]). The risk of early atherogenesis was additionally amplified when high-sHSP60 and chronic infection were
present together.
Conclusions—Our study provides the first prospective data confirming an association between high levels of sHSP60 and
early carotid atherosclerosis. This possibly indicates an involvement of sHSP60 in activating proinflammatory processes
associated with early vessel pathology. (Stroke. 2005;36:2571-2576.)
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Atherosclerosis is a multifactorial process characterizedby accumulation of lipid-laden macrophages and prolif-
erating smooth muscle cells within the vessel wall.1,2 Early
atherosclerotic lesions (fatty streaks) are also characterized
by a comparative abundance of inflammatory cells, like
activated T lymphocytes, mast cells, and macrophages, indi-
cating the involvement of immunoinflammatory processes in
its pathogenesis.1,3,4 One of the candidate antigen, stimulating
recruitment of T cells into the plaque, is increasingly believed
to be bacterial heat shock protein (HSP) 65 (HSP65).5
The HSP60/65 family of chaperone proteins is a group of
evolutionarily conserved proteins with a molecular weight of
60 kDa, which facilitates the folding of newly synthesized
polypeptides in an ATP-dependent manner and plays an
important role in maintaining the dynamic stability of the
intracellular proteome.6–8 Because of their evolutionary con-
servation, HSPs show a high degree of structural homology
all the way from prokaryotes to humans.6–8 Human autoanti-
bodies against HSP60/65 have been shown to be cross-reactive
against chlamydial, mycobacterial, and other bacterial HSPs.9
HSP60, both human and chlamydial, has also been shown to
enhance the production of proinflamatory cytokines, like
tumor necrosis factor  and matrix metalloproteinase produc-
tion in macrophages,10,11 and increase expression of interleu-
kin 6, adhesion molecules like E-selectin, and intercellular
adhesion molecule 1 in vascular endothelial cells.12 Elevated
levels of soluble HSP60 (sHSP60) have been found in
patients with borderline hypertension13 and correlate with
high-carotid intimamedia thickness. In a large population-
based study, we14 have demonstrated previously that levels of
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circulating sHSP60 are associated with the presence and
severity of carotid atherosclerosis and that subjects with high
sHSP60 experienced faster progression of atherosclerosis in
the 5 years before the assessment of sHSP. The correlations
were independent of age, gender, and other established risk
factors. However, these studies do not permit assessment of
the temporal relationship between high sHSP60 levels and
progression of arteriosclerosis. In the current evaluation, we
reassess the association of sHSP60 with progression of
arteriosclerosis during follow-up of the same population. The
hypothesis was that sHSP60 levels predict the progression of
arteriosclerosis during follow-up.
Methods
Study Population
Population recruitment was performed as part of the Bruneck
Study.15,16 The survey area was located in the north of Italy (Bolzano
Province). Special features of the study design and protocol have
been detailed previously.15–17
Clinical Examination and Laboratory Methods
All of the participants completed standardized questionnaires on
current and past exposure to candidate vascular risk factors and
underwent a clinical examination with cardiovascular and neurolog-
ical priority.14,18 Vascular risk factors were assessed by standard
methods as detailed previously.14–18 Subjects with chronic infections
were identified by extensive clinical and laboratory screening as
described previously.18 Briefly, an extensive screening consisting of
2 consecutive phases identified subjects with chronic infections. The
first step involved a detailed self-reported medical and medication
history, thorough clinical examination, spirometry, extensive labo-
ratory evaluations including urinary analysis, and a review of the
Bruneck Hospital databases and other medical records. If the data
were inconclusive, in a second step, individuals were referred for
additional optional examinations. For example, bronchitis was de-
fined as chronic when cough with expectoration lasted 3 months in
2 consecutive years. Urinary tract infections were regarded as
recurrent in the case of 3 documented episodes. Periodontitis was
defined by self-report.
sHSP60 Assay
The serum sHSP60 concentrations were analyzed using a slight
modification of sandwich ELISA described previously.14,19 The two
monoclonal antibodies used were II-13 and N-20 (Santa Cruz
Biotechnology), each reacting against separate nonoverlapping
epitopes of HSP60.
Assays of Antilipopolysaccharide,
Antimycobacterial HSP65, Antichlamydia,
and Anticytomegalovirus Antibodies
The procedure for determining antilipopolysaccharide antibodies
was similar to that described elsewhere.20 Serum anti-HSP65 anti-
bodies were measured using the ELISA technique described
previously.2 Serum antibodies against Chlamydia pneumoniae and
cytomegalovirus (CMV) were determined using the following com-
mercially available assays, as per their instructions: SeroCP-IgA
(Savyon Diagnostics Ltd) and CMV-IgG ELISA (Medac).
Scanning Protocol and Definition of Ultrasound
End Points
The ultrasound protocol involves scanning of the internal (bulbous
and distal segments) and common (proximal and distal segments)
carotid arteries on either side with a 10-MHz imaging probe and
5-MHz Doppler.17,21 Atherosclerotic lesions were identified by 2
ultrasound criteria: (1) wall surface (protrusion into the lumen or
roughness of the arterial boundary); and (2) wall texture (echo-
genicity). Accuracy of this procedure has been established previ-
ously.15 Incident atherosclerosis was defined by the occurrence of
atherosclerotic lesions in vessel segments initially free of atheroscle-
rosis and progression of nonstenotic lesions by a relative increase in
the plaque diameter exceeding twice the measurement error of the
method.15,17,21 Both processes were combined to a single outcome
category called “early atherogenesis.”15 Incident vessel stenosis was
assumed whenever the progression criterion was met and a narrow-
ing of the lumen 40% occurred. This stage of atherogenesis was
termed “advanced atherogenesis.”12–15 The 2 progression categories
were highly reproducible ( coefficients 0.8; n100).
Statistical Analysis
Correlations between sHSP60 and other parameters were estimated
by Spearman rank correlation coefficients. Strength and type of
association between baseline sHSP60 (1995) and various stages of
atherogenesis (1995 to 2000) were assessed by logistic regression
analysis, with the test procedure based on maximum likelihood
estimators. The accuracy of fit of each model was assessed by the
test of Hosmer and Lemeshow. As to early atherogenesis (5-year
incidence/progression of carotid atherosclerosis), separate equations
were fitted in the entire population (n684) and in subjects free of
atherosclerosis at the 1995 evaluation. Base models were adjusted
for age and genderbaseline atherosclerosis. Multiple regression
analyses were adjusted for fixed sets of covariates that were assessed
in previous analyses of the vascular risk profile of the Bruneck study
population.15 sHSP60 was loge transformed and odds ratios (95% CI)
were calculated for a 1-SD unit increase in variable levels. In
additional analysis, quintile groups of sHSP60 were modeled as a set
of indicator variables. We performed a test for linear trend by
treating the medians in each category of sHSP60 as a continuous
variable.
The current analysis and the manner of risk factor adjustment were
prespecified to avoid multiple testing. Calculations were performed
using the SPSS 11.5 and BMDP software packages. A 2-sided
P0.05 was considered significant.
Results
In 232 (33.9%) study subjects, serum HSP60 was not detect-
able. In the rest of cohort, the median sHSP60 level was 68
ng/mL, with a range of 0 to 11 000 ng/mL. A total of 37
subjects (5.4%) had sHSP60 concentrations 1000 ng/mL;
such high concentrations have been shown to cause maximal
activation of macrophages and endothelial cells in vitro.10–12
sHSP60 levels measured in 1995 and in 2000 were highly
correlated (r0.40; P0.001), indicating that an individual
sHSP60 level may be a consistent characteristic during a
5-year period.
Of 684 subjects, 330 showed early atherogenesis; that is,
they developed new atheroslcerotic lesions or showed pro-
gression of preexisting nonstenotic plaques. Among the 350
subjects free of carotid atherosclerosis at the 1995 evaluation,
75 developed first atherosclerotic plaques.
Table 1 lists the means and proportions of selected demo-
graphic characteristics and risk factors in the study popula-
tion. Additional details have been presented previously.14 A
large number of epidemiological studies have reported about
the association between atherosclerosis and various persistent
bacterial and viral infections, including chlamydia and
CMV.22–25 We were able to show positive correlations be-
tween sHSP60 and antipathogen/anti-HSP antibodies in both
the 1995 and 2000 evaluation. In both the 1995 and 2000
evaluation, we were able to show positive correlations of
sHSP60 with anti-LPS antibodies (r0.37 and 0.28;
P0.001 each), anti-HSP65 antibodies (r0.21 and 0.27;
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P0.001 each), and anti-HSP60 antibodies [r0.26 (mea-
sured in 2000 only); P0.001]. Correlations were weak and,
in part, inconsistent for antichlamydia IgA (r0.08 and 0.07;
P0.035 and 0.08) and anti-CMV IgG (r0.02 and 0.09;
P0.59 and P0.02). This has been detailed in Table 2. In
addition, high levels of sHSP60 were more common among
subjects with chronic infections than in those without (top
quintile group of HSP60: 23.8% versus 17.0%, P0.003 after
adjustment for age and sex). No correlation was found to exist
between C-reactive protein level and sHSP60.
Loge-transformed sHSP60 levels were significantly associ-
ated with early atherogenesis both in the entire population
and subgroup free of atherosclerosis at 1995 baseline (Table
3). To rule out confounding by other vascular risk factors,
multiple logistic regression models were adjusted for age,
gender, baseline atherosclerosis, smoking, hypothyreosis, hy-
pertension, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, microalbuminuria, ferritin, and alco-
hol consumption (Table 2). The association between sHSP60
and early atherosclerosis progression was similar in both
genders and all age groups (data not presented). Figure 1
illustrates the relationship between early atherogenesis and
sHSP60 quintile groups (quintile III was used as the
reference group). Significant associations were obtained in
both the base and multivariate models and in the entire
population and the subgroup free of atherosclerosis at the
1995 baseline. In the latter group, a gradual increase of risk,
across the quintile groups, was found. Presence of chronic
infection enhanced the predictive significance of sHSP for
early atherogenesis (Figure 2). For example, in the subgroup
TABLE 1. Descriptive Characteristics of the Study
Population (n684)
Variable MeanSD or n (%) or Median (IQR)
Age, y 56.010.2
Female gender, n (%) 354 (51.8)
Hypertension, n (%) 238 (34.8)
Smoking, n (%) 130 (19.0)
Alcohol consumption, n (%) 348 (50.9)
Chronic infection, n (%) 160 (23.4)
LDL cholesterol, mg/dL 146.037.5
HDL cholesterol, mg/dL 58.816.1
Ferritin concentration, g/dL 82.0 (33.1–155.8)
Microalbuminuria, g/L 9.0 (7.0–16.0)
Hypothyroidosis, n (%) 58 (8.5)
IQR indicates interquartile range; LDL, low-density lipoprotein; HDL,
high-density lipoprotein.
TABLE 2. Correlation of sHSP60 With Demographic Variables, Vascular Risk Factors, and Antipathogen Antibodies
Variable
Subjects Without AS
1995 (n350)
Subjects With AS
1995 (n334)
All Subjects
1995 (n684)
All Subjects
2000 (n684)
r* P r* P r* P r* P
Age 0.06 0.30 0.06 0.25 0.09 0.01 0.02 0.63
Smoking 0.08 0.13 0.03 0.56 0.05 0.18 0.07 0.07
LDL 0.03 0.54 0.04 0.48 0.04 0.26 0.01 0.84
HDL 0.06 0.25 0.01 0.85 0.04 0.31 0.03 0.38
Systolic blood pressure 0.04 0.43 0.03 0.60 0.06 0.11 0.08 0.05
Diastolic blood pressure 0.10 0.06 0.05 0.39 0.03 0.45 0.09 0.03
TSH 0.01 0.81 0.03 0.61 0.02 0.69 0.05 0.18
Microalbuminuria 0.03 0.61 0.02 0.68 0.01 0.81 0.03 0.39
Ferritin 0.03 0.52 0.16 0.003 0.11 0.003 0.06 0.11
C-reactive protein 0.07 0.17 0.01 0.79 0.01 0.81 0.06 0.14
Anti-HSP65 AB 0.16 0.002 0.25 0.001† 0.21 0.001† 0.27 0.001†
Antihuman HSP60 AB NA NA NA 0.26 0.001†
Anti-LPS AB 0.36 0.001† 0.36 0.001† 0.37 0.001† 0.28 0.001†
Anti-chlamydial IgG 0.11 0.03 0.07 0.21 0.08 0.04 0.07 0.08
Anti-CMV AB 0.02 0.76 0.06 0.26 0.02 0.59 0.09 0.02
AS indicates atherosclerosis; AB, antibodies; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LPS lipopolysaccharide; TSH,
thyroid-stimulating hormone; NA, not available; *Data presented are Spearman rank correlation coefficients; †Correlations remain significant after
accounting for the multiple comparisons performed.
TABLE 3. Association of sHSP60 With Early Atherogenesis in
the Carotid Arteries (1995–2000)
Variable Odds Ratio (95% CI) P Value
Entire study population (n684)
Soluble HSP60* 1.20 (1.00 to 1.45) 0.05
Soluble HSP60† 1.26 (1.04 to 1.54) 0.02
Subjects free of AS at baseline (n350)
Soluble HSP60* 1.49 (1.11 to 2.01) 0.008
Soluble HSP60† 1.55 (1.12 to 2.14) 0.002
Odds ratios were calculated for a 1-SD increase in loge-transformed sHSP60
levels. They were derived from logistic regression analysis. *Adjusted for age,
gender, baseline atherosclerosis (AS); †Adjusted for age, gender, baseline
atherosclerosis, smoking, hypothyreosis, hypertension, high-density lipoprotein
and low-density lipoprotein, cholesterol, microalbuminuria, ferritin concentra-
tion, and alcohol consumption.
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free of atherosclerosis in 1995, the odds ratio for incident
carotid atherosclerosis was 2.0 in subjects with high sHSP60,
but this increased to 4.2 when high sHSP60 coexisted with
chronic infection (Figure 2A). No association, however, was
found to exist between sHSP60 and advanced atherogenesis
[multivariate odds ratio (95%CI) calculated for a 1-SD unit
increase in loge-transformed sHSP60 0.92 (0.69 to 1.23),
P0.59].
Discussion
We have previously shown an association between sHSP60
and severity of atheroslcerosis,14 which has been subse-
quently confirmed by other groups,13,19 but most of these
studies were cross-sectional. In this study, we provide the
first truly prospective data and demonstrate that subjects with
sustained elevation of sHSP60 in their blood are at an
increased risk of early atherogenesis in the carotid arteries
(development and progression of nonstenotic atherosclerotic
lesions). These findings could be potentially relevant to a
better understanding of the role of circulating autoantigens in
atherogenesis.
Proteins of the HSP60 family are mostly located in the
intracellular compartment (mitochondria and cytosol) and are
only expressed on the cell surface under stressful condi-
tions.26–28 In this study, we were able to demonstrate a
sustained presence of circulating sHSP60 in human blood,
over a 5-year observation period. The exact nature and
composition of the measured sHSP60 in human serum is yet
to be established, but there are a few possibilities. One of the
likely sources could be infectious agents, like chlamydia,
especially during the lytic phases of their life cycle.29 The
association between sHSP60 and antipathogen antibodies and
Figure 1. Association of quintile groups for sHSP60 with early atherogenesis in the carotid arteries (1995–2000). Quintiles QIII (0 to 40
ng/mL) serve as a reference category. Odds ratio (95% CI) for each category is listed above the bar. P values are for linear trend. Anal-
ysis in A was adjusted for age, gender, and baseline atherosclerosis. Analysis in B was adjusted for age, gender, baseline atherosclero-
sis, smoking, hyopthyroidosis, hypertension, high-density lipoprotein and low-density lipoprotein cholesterol, microalbuminuria, ferritin
concentration, and alcohol consumption. *P0.05; **P0.01.
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chronic infection in our study and in other reports14 and their
colocalization in human atheromas10 lend additional support
to this theory. Alternatively, surface-expressed HSP6026,30 on
stressed cells undergoing apoptosis may be released into the
circulation as microparticles. This is corroborated by the
finding of circulating microparticles in patients with acute
coronary syndrome31 and its correlation with the degree of
endothelial dysfunction in these patients.32
In our study, we were able to demonstrate an association
between sHSP60 and early but not advanced carotid athero-
sclerosis. It is interesting that a positive correlation has been
demonstrated to exist between peripheral blood T cells
reactive to HSP60 and the extent of early vessel pathology as
indicated by a high-carotid intimamedia thickness in young
army recruits.33 However, a similar association could not be
demonstrated in middle-aged and elderly people with ad-
vanced atherosclerosis, suggesting that immunity may have a
preferential role in early stages of atherosclerosis.
Previous studies have shown that T cells in human ather-
omas are mostly T-helper 1 cells bearing the / receptor;34
however, in the earliest stages of atherosclerosis, there is a
relative abundance of T cells bearing the / receptor.34,35
One of the probable antigens recognized by these T cells is
HSP, a hypothesis supported by the isolation of T cells from
rabbit atheromas5 and atherosclerotic plaques obtained from
humans,36 specifically responding to HSP60/65. Interleukin
2-expanded T-cell lines derived from atherosclerotic lesions
showed a significantly higher HSP60/65 reactivity compared
with the cells derived from peripheral blood of the same
donor. Recent work by Zal et al37 demonstrated increased
numbers of CD4CD28null T cells in the peripheral blood of
patients with acute coronary syndrome in comparison to those
with chronic stable angina. These natural killer cells were
found to be activated by human HSP60 but not cytotomega-
lovirus, C. pneumonia, oxidized low-density lipoprotein, or
lipopolysaccharide in a MHC class II-dependent manner.
This observation additionally supports the role of HSP60 as
an important autoantigen involved in atherosclerosis.
The presence of chronic infection further enhanced the
predictive significance of sHSP for early atherogenesis
(Figure 2). sHSP60 is known to mediate adhesion of
monocytes to endothelial cells via the CD14 receptor.38 It
has also been suggested that HSP60 has a cytokine-like
function39 and elicits a release of tumor necrosis factor 
from macrophages, causing expression of E-selectin, in-
tercellular adhesion molecule 1, and vascular cell adhesion
molecule 1.11,12 A total of 5.4% of the subjects in our study
had concentrations 1000 ng/mL. Such high concentra-
tions have been demonstrated in various in vitro studies to
maximally activate macrophages, endothelial cells,11,12 and
T cells.37 Similarly, the presence of infections will not only
supplement these proinflammatory responses but may also
enhance the pool of circulating HSPs22–25 and lead to the
development of early atherosclerosis.40
In summary, we provide the first truly prospective data
confirming an association of sustained elevation of sHSP60
levels with early carotid atherosclerosis. This finding is
consistent with the involvement of innate and adaptive
immunity in atheroslcerosis and lends additional support to
the role of HSP60 as an important candidate autoantigen.
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